A recent report shows that the anthraquinone oxime-analog BC2059 attenuates the expression of β-catenin in AML cells with and without an internal tandem duplication of the leukemogenic kinase FMS-like tyrosine kinase (FLT3-ITD) through a proteasomal mechanism. Here, FLT3 is linked to acute myeloid leukemia.